$TMDX

TransMedics Group, Inc.

TransMedics is a medical technology company that develops organ preservation systems and services for transplant programs treating patients with end-stage organ failure. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated, nutrient-enriched blood. TransMedics offers organ-specific OCS products for heart, lung and liver transplantation, along with consoles, single-use perfusion sets and nutrient-enriched solutions. The company has also initiated development of OCS Kidney. TransMedics provides its National OCS Program (NOP), an outsourced service for organ procurement, OCS perfusion management and transplant logistics, including aviation and ground transportation. It also sells OCS products directly to transplant centers, which train their own teams to use the system. Its business model derives recurring revenue primarily from single-use disposable sets required for each OCS transplant and services provided through the NOP. TransMedics is headquartered in Andover, Massachusetts.

0
1
0
—
$385K
TOBIN JAMES R
0%
See all $TMDX insider activity →
Low

TransMedics Earnings Call Highlights Record Growth

TransMedics (TMDX) reported Q3 2026 revenue of $203M, up 41% YoY, with strong growth in liver and heart transplants. Revenue guidance raised to $764M-$774M. Margins improved excluding PAD Aviation. International expansion and clinical studies progress noted.

TOBIN JAMES R sold $385K of TMDX

TOBIN JAMES R sold 4,059 shares of TransMedics Group, Inc. (TMDX) at an average of $94.97 ($93.96–$94.98, $0.39M total) across 2 trades on 2026-11-09.

TMDX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning TMDX (TransMedics Group, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent TMDX coverage spans financial news, earnings and insider activity.

In the last 30 days, TMDX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($385K). The most active reporter was TOBIN JAMES R with 2 filings.

What's driving TMDX

  • Strong earnings recap may sustain modest bullish sentiment but limited new catalyst.

    tipranks.com · Nov 15, 2026

  • The insider sale may signal modest concern and could exert slight downward pressure on the stock.

    SEC EDGAR · Nov 12, 2026

  • JP Morgan kept its 'Neutral' rating on TransMedics Group but raised its price target to $85 from $73, a 16.4% increase. The new target suggests a 3.7% downside from the Nov 6 close of $88.24. Other recent analyst targets for the company range from $110 to $120.

    tradingview.com · Nov 7, 2026

  • Needham reaffirmed its Buy rating for TransMedics Group and increased its price target to $110 from $106, suggesting a 59.5% upside from the Nov 5 close of $68.98.

    tradingview.com · Nov 6, 2026

  • Canaccord Genuity kept its Buy rating on TransMedics Group and raised its price target to $120 from $95, citing a 74% potential upside from the Nov 5 close of $68.98.

    tradingview.com · Nov 6, 2026

AlphAI scores every news story that mentions TMDX with an AI model for sentiment and relevance, and aggregates insider trades from TransMedics Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TMDX

Score

TransMedics (TMDX) Q3 2026 Earnings Call Transcript

TransMedics (TMDX) reported Q3 2026 revenue of $203M, up 41% YoY. Transplant product revenue grew 29% YoY to $113M, while service revenue increased 44% YoY to $79M. The company expects growth to accelerate due to ongoing initiatives. Cash reserves totaled $493M. TransMedics advanced clinical programs for heart and lung transplants, with FDA approvals for key studies. European expansion and kidney transplant developments are also underway.

Related tickers